Long COVID Atlas
Text Theme
Note

Education, not medical advice. Do not start, stop, or change any medication or supplement without your own clinician, who knows your history and other medicines.

Treatment · Supplement

Oxaloacetate

A metabolic supplement aimed squarely at long COVID fatigue. Early results looked striking, but the study design and funding warrant caution, and the evidence is not yet strong enough to call it effective.

Short version: oxaloacetate is a supplement that may reduce long COVID fatigue, but the early evidence is industry-funded with methodological caveats. Interesting signal, not yet proven.

A metabolic supplement for fatigue

Oxaloacetate is a molecule in the cell's energy cycle. The idea is that supplementing it supports mitochondrial energy production and reduces the fatigue that defines so much of long COVID.1

When the cell's batteries run low mitochondria: the cell's power plants less usable energy (ATP) fatigue, lowstamina, slowrecovery
Inside every cell, mitochondria turn fuel into usable energy. In long COVID the muscle studies show these power plants working less efficiently and the muscle leaning on a lower-yield backup process. Less energy produced, for the same effort, is felt as fatigue, poor stamina, and slow recovery, and it worsens after exertion.

What the evidence says

An open-label study reported meaningful fatigue reduction in long COVID and ME/CFS, and a randomized follow-on has been run. But the early study was industry-funded with a historical (not concurrent) placebo, and editorial concerns have been raised, so the result needs cautious reading.1, 2

preliminary funding/method caveats

Honest framing

It is a supplement, not an approved drug, generally well tolerated but not cheap. The signal on fatigue is interesting; the evidence quality is not yet strong enough to call it effective.

What we don't know

Honest about the edges of the evidence. These are open questions, not settled answers.

  • Whether benefit holds up in independent, concurrently controlled trials.
  • The right dose.
  • Who responds.
  • Cost-effectiveness versus other approaches.

References

Every reference is free to read in full.

  1. Oxaloacetate for fatigue in ME/CFS and long COVID (non-randomized trial; note funding and editorial caveats).
  2. REGAIN: randomized trial of oxaloacetate for long COVID (2025).

Associated topics